Maria Patricia Rivera

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Lung cancer in women: the differences in epidemiology, biology and treatment outcomes
    Maria Patricia Rivera
    University of North Carolina at Chapel Hill, 4133 Bioinformatics Building CB 7020, Chapel Hill, NC 27516, USA
    Expert Rev Respir Med 3:627-34. 2009
  2. doi request reprint Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
    M Patricia Rivera
    Department of Medicine, University of North Carolina at Chapel Hill, 4133 Bioinformatics Bldg, CB No 7020, Chapel Hill, NC 27599, USA
    Chest 143:e142S-65S. 2013
  3. doi request reprint Preinvasive lesions of the bronchus
    M Patricia Rivera
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill, 4133 Bioinformatics Building, Mason Farm Road, CB 7020, Chapel Hill, NC 27516, USA
    Clin Chest Med 32:693-702. 2011
  4. doi request reprint Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer
    M Patricia Rivera
    Multidisciplinary Thoracic Oncology Group, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7248, USA
    Chest 135:1588-95. 2009
  5. ncbi request reprint Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
    M Patricia Rivera
    University of North Carolina at Chapel Hill, 4133 Bioinformatics Building, CB No 7020, Chapel Hill, NC 27599, USA
    Chest 132:131S-148S. 2007
  6. ncbi request reprint Management of patients with advanced non-small-cell lung cancer
    M P Rivera
    Department of Pulmonary and Critical Care Medicine, University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27599 7020, USA
    Curr Opin Pulm Med 7:247-58. 2001
  7. ncbi request reprint Diagnosis of lung cancer: the guidelines
    M Patricia Rivera
    Department of Medicine, The University of North Carolina at Chapel Hill, 420 Burnett Womack Boulevard, CB No 7020, Chapel Hill, NC 27599, USA
    Chest 123:129S-136S. 2003
  8. ncbi request reprint Gender and lung cancer
    M Patricia Rivera
    Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, 4133 Bioinformatics Building CB 7020, Chapel Hill, NC 27599, USA
    Clin Chest Med 25:391-400. 2004
  9. ncbi request reprint Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:4341-50. 2004
  10. doi request reprint The prevalence of clinically relevant incidental findings on chest computed tomographic angiograms ordered to diagnose pulmonary embolism
    William B Hall
    Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Campus Box 7020, 130 Mason Farm Rd, Chapel Hill, NC 27514
    Arch Intern Med 169:1961-5. 2009

Detail Information

Publications22

  1. ncbi request reprint Lung cancer in women: the differences in epidemiology, biology and treatment outcomes
    Maria Patricia Rivera
    University of North Carolina at Chapel Hill, 4133 Bioinformatics Building CB 7020, Chapel Hill, NC 27516, USA
    Expert Rev Respir Med 3:627-34. 2009
    ....
  2. doi request reprint Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines
    M Patricia Rivera
    Department of Medicine, University of North Carolina at Chapel Hill, 4133 Bioinformatics Bldg, CB No 7020, Chapel Hill, NC 27599, USA
    Chest 143:e142S-65S. 2013
    ..The objective of this study was to determine the test performance characteristics of various modalities for the diagnosis of suspected lung cancer...
  3. doi request reprint Preinvasive lesions of the bronchus
    M Patricia Rivera
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill, 4133 Bioinformatics Building, Mason Farm Road, CB 7020, Chapel Hill, NC 27516, USA
    Clin Chest Med 32:693-702. 2011
    ..Molecular alterations have been described in preinvasive lesions and may help better predict which lesions will progress. Several noninvasive techniques are available for the treatment of high-grade lesions...
  4. doi request reprint Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer
    M Patricia Rivera
    Multidisciplinary Thoracic Oncology Group, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7248, USA
    Chest 135:1588-95. 2009
    ....
  5. ncbi request reprint Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition)
    M Patricia Rivera
    University of North Carolina at Chapel Hill, 4133 Bioinformatics Building, CB No 7020, Chapel Hill, NC 27599, USA
    Chest 132:131S-148S. 2007
    ....
  6. ncbi request reprint Management of patients with advanced non-small-cell lung cancer
    M P Rivera
    Department of Pulmonary and Critical Care Medicine, University of North Carolina Chapel Hill, Chapel Hill, North Carolina 27599 7020, USA
    Curr Opin Pulm Med 7:247-58. 2001
    ..The performance status of patients with advanced non-small-cell lung cancer is the most important determinant of response to chemotherapy...
  7. ncbi request reprint Diagnosis of lung cancer: the guidelines
    M Patricia Rivera
    Department of Medicine, The University of North Carolina at Chapel Hill, 420 Burnett Womack Boulevard, CB No 7020, Chapel Hill, NC 27599, USA
    Chest 123:129S-136S. 2003
    ..Recommendations are graded in terms of strength to provide clinicians with guidance as to the most efficient and approach to the diagnosis of lung cancer in individual patients...
  8. ncbi request reprint Gender and lung cancer
    M Patricia Rivera
    Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, 4133 Bioinformatics Building CB 7020, Chapel Hill, NC 27599, USA
    Clin Chest Med 25:391-400. 2004
    ..When guidelines for screening, preventive therapies, and treatment options for lung cancer are outlined these differences should be considered...
  9. ncbi request reprint Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:4341-50. 2004
    ..Dose escalation using three-dimensional thoracic conformal radiation therapy (TCRT) is one strategy to improve local control and perhaps survival...
  10. doi request reprint The prevalence of clinically relevant incidental findings on chest computed tomographic angiograms ordered to diagnose pulmonary embolism
    William B Hall
    Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Campus Box 7020, 130 Mason Farm Rd, Chapel Hill, NC 27514
    Arch Intern Med 169:1961-5. 2009
    ..Our objective was to determine the prevalence and management implications of incidental findings on chest CTAs ordered to assess for PE...
  11. doi request reprint Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer
    Carrie B Lee
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center at University of North Carolina at Chapel Hill, North Carolina, USA
    J Thorac Oncol 4:74-9. 2009
    ..Dose escalation of radiotherapy is one strategy used to improve locoregional control and survival, but it increases the risk of both early and late treatment related toxicities...
  12. doi request reprint Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer
    Thomas E Stinchcombe
    Division of Hematology Oncology, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:1279-85. 2008
    ....
  13. doi request reprint Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, 3009 Old Clinic Building CB 7305, Chapel Hill, NC 27599 7305, USA
    J Thorac Oncol 3:250-7. 2008
    ..We investigate the tolerability of gefitinib in combined modality therapy in combination with three-dimensional thoracic conformal radiation therapy (3-dimensional TCRT)...
  14. ncbi request reprint Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses
    Frank C Detterbeck
    Division of Cardiothoracic Surgery, Department of Surgery, University of North Carolina at Chapel Hill, USA
    Chest 125:2294-9. 2004
    ....
  15. ncbi request reprint Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA
    J Thorac Oncol 2:819-26. 2007
    ..Physicians' beliefs and practice patterns may differ significantly from established guidelines. We conducted a survey to assess and compare physician beliefs against the evidence-based guidelines...
  16. ncbi request reprint Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer
    Frank C Detterbeck
    Division of Cardiothoracic Surgery, Department of Surgery, Members of the Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, NC, USA
    Chest 125:2300-8. 2004
    ..It is unclear and controversial whether a biopsy is needed in patients with clinical stage II lung cancer who have no PET uptake in the mediastinum...
  17. ncbi request reprint Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma
    Suzanne E Biehn
    University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599 7295, USA
    Hematol Oncol 24:234-7. 2006
    ..Physicians utilizing rituximab should be aware of this association given the difficulty of differentiating between presentations of BOOP and neoplastic pulmonary processes...
  18. ncbi request reprint Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists
    Gerard A Silvestri
    Medical University of South Carolina, Room 812 CSB, 171 Ashley Ave, Charleston, SC 29425, USA
    Chest 128:3975-84. 2005
    ..It is important for pulmonologists to be aware of this class of compounds, as they can provide benefit to patients with NSCLC who may not have been previously considered for antitumor therapy...
  19. ncbi request reprint Guidelines on treatment of stage IIIB non-small cell lung cancer
    James R Jett
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Chest 123:221S-225S. 2003
    ..Treatment of stage IIIB due to malignant pleural effusion is addressed in the section that deals with stage IV disease...
  20. ncbi request reprint Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells
    Hyeon Woo Yim
    Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
    Cancer Lett 246:24-33. 2007
    ..An increase in telomerase activity in normal bronchial epithelium might extend the lifespan of cells at risk for malignant transformation, and thus contribute to lung carcinogenesis...
  21. ncbi request reprint Chromosomal abnormalities in bronchial epithelium from smokers, nonsmokers, and lung cancer patients
    Robbert J C Slebos
    Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
    Cancer Genet Cytogenet 159:137-42. 2005
    ..These specific alterations were found almost exclusively in patients with a history of tobacco smoking. The results did not indicate that general chromosomal abnormalities are a useful marker for tobacco smoke exposure or cancer risk...
  22. ncbi request reprint Detection of pre-invasive lung cancer: technical aspects of the LIFE project
    Gordon P Flake
    Laboratory of Experimental Pathology, National Institute of Environmental Sciences, NIH, Research Triangle Park, NC 27709, USA
    Toxicol Pathol 35:65-74. 2007
    ....